Except in the 35-36-week subgroups, the recurrence rates of ROP in the GA subgroups of the high-dose group was significantly lower than those in the same subgroups of the conventional-dose group, perhaps because the reduction in VEGF level by the high injection dose promoted the disappearance of neovascularization. This evidence concerns the gene VEGFA and retinopathy of prematurity.